Stocktoria
Cytek Biosciences, Inc. CTKB
Nasdaq · XNAS · stock · Laboratory Analytical Instruments · website · IPO 2021-07-23
Cytek Biosciences, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $201.5M | $200.5M | $193.0M | $164.0M | $128.0M |
| Gross profit | $104.5M | $111.1M | $109.4M | $101.0M | $79.1M |
| R&D expense | $36.5M | $39.4M | $44.2M | $34.9M | $24.4M |
| Operating income | -$40.4M | -$20.5M | -$27.8M | -$1.8M | $9.2M |
| Interest expense | — | — | $2.1M | $2.6M | $1.7M |
| Income tax | $36.7M | $320,000 | -$3.6M | -$1.2M | $2.9M |
| Net income | -$66.5M | -$6.0M | -$12.1M | $2.5M | $3.0M |
| EPS (diluted) | — | — | $-0.09 | $0.02 | $0.00 |
| Operating cash flow | -$4.7M | $25.4M | $5.3M | -$12.2M | $4.6M |
| Free cash flow | -$8.8M | $21.9M | $633,000 | -$22.0M | $266,000 |
| Cash & equivalents | $90.9M | $98.7M | $167.3M | $296.6M | $364.6M |
| Inventory | $48.4M | $43.9M | $60.9M | $48.2M | $32.2M |
| Total assets | $461.5M | $499.5M | $494.5M | $519.5M | $463.3M |
| Total liabilities | $119.8M | $103.8M | $101.4M | $93.9M | $57.9M |
| Shareholders' equity | $341.7M | $395.7M | $393.1M | $425.5M | $405.4M |
Source: SEC EDGAR filings · CIK 0001831915 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.